Pharmaceuticals
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...
2022-04-13 06:00
1773
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administrati...
2022-04-12 20:55
1371
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States
CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...
2022-04-12 15:45
1375
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...
2022-04-12 15:34
2722
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
1702
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3745
AGC to Expand Synthetic Pharmaceutical Production Base in Spain
TOKYO, April 8, 2022 /PRNewswire/ -- AGC Inc. (hereinafter "AGC"), a Tokyo -based world-leading manufacturer of glass, chemicals, high-tech materials, has decided to expand the facilities of AGC Pharma Chemicals Europe S.L.U. (hereinafter "APCE"), an AGC subsidiary in Spain engaged in the syntheti...
2022-04-08 14:00
2388
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
3371
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epid...
2022-04-07 19:47
1958
Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada
TAIPEI, April 6, 2022 /PRNewswire/ -- Bened Biomedical announced recent approval of the company's probioticL. plantarum PS128 in Thailand and Canada. Authorities in each country also endorsed health claims that may be made about the strain. Local distributors will launch PS128 products this year....
2022-04-07 11:20
2201
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
* The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO, April 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treat...
2022-04-07 09:34
3048
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 6, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston -based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, ...
2022-04-07 04:00
2711
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical comp...
2022-04-06 22:30
2960
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment ofSharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro d...
2022-04-06 20:00
3879
Kintor Pharma's Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
* Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p <0.02). * Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors. * Proxalutamid...
2022-04-06 09:22
2249
Nihon Medi-Physics Attains World's First Manufacturing of Actinium-225 with Cyclotron on Production Scale for Investigational Drugs
- Core Material Used for Targeted Alpha Therapy (TAT) Expected to Be Novel Treatment for Cancer - TOKYO, April 5, 2022 /PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company inJapan, announced on April 5, 2022, that the company has successfully manufactured act...
2022-04-05 16:00
2693
Indonesia's Ministry of Health Discussed a Universal Vaccine Passport and Verifier for International Travelers
JAKARTA, April 4, 2022 /PRNewswire/ -- Assuming the presidency in the upcoming
G20 summit,Indonesia has begun the Health Working Group (HWG) meeting series
that took place on28-30 March 2022 in Yogyakarta, Indonesia.
2022-04-04 23:35
2608
Dada's JDDJ in action to guarantee medical supply and online health consultation with pharmaceutical partners
SHANGHAI, April 2, 2022 /PRNewswire/ -- As a number of cities in China are ramping up anti-epidemic measures, more consumers rely on online-to-offline services to purchase much-needed medications. JDDJ, one ofChina's largest local on-demand retail platforms operated by Dada Group (Nasdaq: DADA), ...
2022-04-02 20:53
4096
Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers
SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...
2022-04-01 16:55
2081
Akeso Reported 2021 Annual Results
Penpulimab Started Commercialization and Cadonilimab Filed for NDA HONG KONG, April 1, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology,...
2022-04-01 13:44
25607
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
8352
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
8293
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
8156
